Tecovirimat for Monkeypox (PLATINUM-CAN Trial)

"Indeed, the details on clinicaltrials.gov demonstrate that this investigation is actively seeking suitable participants. The trial was initially disclosed on August 14th, 2023, with its most recent update made on February 28th, 2024. At present, the study aims to recruit a total of 120 individuals from three distinct sites."

"Based on the information provided, our team at Power rates Tecovirimat's safety as a 3 on the scale. This assessment is influenced by the Phase 3 trial status which signifies partial efficacy evidence and robust safety data from multiple iterations."

"Yes, information on clinicaltrials.gov highlights that this research is presently in search of volunteers. The initial posting date was 8/14/2023, with the latest update recorded on 2/28/2024. A total of 120 participants are sought across three distinct sites."

"The primary aim of this investigation, to be assessed within an approximate time frame extending up to 28 days from randomization, is to evaluate the feasibility and acceptability of executing a pragmatic phase 3 intervention trial for outpatients affected by Monkeypox in Canada. Secondary objectives comprise measuring the duration required for complete lesion resolution (defined as the number of days until all lesions have fully healed), determining the timeframe needed for throat swab viral culture results to consistently show negative readings for monkeypox virus, and assessing additional feasibility metrics such as adherence rates exceeding 85% on daily questionnaires and self-sampling practices, alongside tracking participant capability in"